This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Dynavax Technologies（DVAX）株式概要
ダイナバックス・テクノロジーズ・コーポレーションは商業段階のバイオ医薬品会社で、米国および国際的なワクチンの開発・商業化に注力している。 詳細
DVAX Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Dynavax Technologies Corporation 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$15.50 |
| 52週高値 | US$15.73 |
| 52週安値 | US$9.20 |
| ベータ | 0.93 |
| 1ヶ月の変化 | 0.58% |
| 3ヶ月変化 | 37.66% |
| 1年変化 | 22.05% |
| 3年間の変化 | 36.68% |
| 5年間の変化 | 58.49% |
| IPOからの変化 | -83.51% |
最新ニュース
ナラティブの更新 • Feb 05
DVAX: Cash Acquisition By Sanofi Will Likely Unlock Further Upside
Analysts kept their fair value estimate for Dynavax Technologies steady at US$25.00. They refined inputs such as a slightly higher discount rate, modestly adjusted revenue growth and profit margin assumptions, and a small change in the future P/E they use in their models to better reflect their updated view of the company.ナラティブの更新 • Jan 22
DVAX: Planned Takeover Will Likely Unlock Upside From Cash Deal
Analysts have maintained their fair value estimate for Dynavax Technologies at US$25.00, with only minor adjustments to assumptions such as discount rate, revenue growth, profit margin, and future P/E to reflect updated views on the company’s risk profile and earnings potential. What's in the News Sanofi agreed to acquire Dynavax Technologies for US$1.9b in cash, valuing shares at US$15.50 each.ナラティブの更新 • Jan 07
DVAX: Planned Sanofi Acquisition Will Likely Unlock Upside From Conservative Outlook
Analysts have revised their price target on Dynavax Technologies from $32.00 to $25.00, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that indicate a more conservative fair value outlook. What's in the News Sanofi agreed to acquire Dynavax Technologies for a total consideration of US$1.9b, with Dynavax shareholders to receive US$15.50 in cash per share upon completion of the transaction.Recent updates
ナラティブの更新 • Feb 05
DVAX: Cash Acquisition By Sanofi Will Likely Unlock Further Upside
Analysts kept their fair value estimate for Dynavax Technologies steady at US$25.00. They refined inputs such as a slightly higher discount rate, modestly adjusted revenue growth and profit margin assumptions, and a small change in the future P/E they use in their models to better reflect their updated view of the company.ナラティブの更新 • Jan 22
DVAX: Planned Takeover Will Likely Unlock Upside From Cash Deal
Analysts have maintained their fair value estimate for Dynavax Technologies at US$25.00, with only minor adjustments to assumptions such as discount rate, revenue growth, profit margin, and future P/E to reflect updated views on the company’s risk profile and earnings potential. What's in the News Sanofi agreed to acquire Dynavax Technologies for US$1.9b in cash, valuing shares at US$15.50 each.ナラティブの更新 • Jan 07
DVAX: Planned Sanofi Acquisition Will Likely Unlock Upside From Conservative Outlook
Analysts have revised their price target on Dynavax Technologies from $32.00 to $25.00, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that indicate a more conservative fair value outlook. What's in the News Sanofi agreed to acquire Dynavax Technologies for a total consideration of US$1.9b, with Dynavax shareholders to receive US$15.50 in cash per share upon completion of the transaction.分析記事 • Jan 06
Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 42% Yet Its Low P/S Is No Reason For Excitement
Dynavax Technologies Corporation ( NASDAQ:DVAX ) shares have continued their recent momentum with a 42% gain in the...
ナラティブの更新 • Dec 18
DVAX: Buybacks Will Support Future Upside As Pipeline Progress Strengthens Outlook
Analysts have nudged their price target on Dynavax Technologies higher to approximately $19.25 per share. This reflects slightly adjusted assumptions for discount rates, long term revenue growth, profit margins, and forward valuation multiples, which leave their overall fair value estimate broadly unchanged.ナラティブの更新 • Dec 04
DVAX: Share Buybacks Will Drive Future Upside Despite Lowered Market Multiple
Analysts have trimmed their price target on Dynavax Technologies from 21.80 dollars to 19.25 dollars, reflecting slightly higher discount rate assumptions and a more conservative view on future valuation multiples, despite largely unchanged long term growth and margin expectations. What's in the News Board of Directors authorized a new share repurchase plan in October 2025, enabling the company to buy back common stock.ナラティブの更新 • Nov 20
DVAX: Share Repurchase And Positive Trial Data Will Drive Further Upside
Analysts have revised their price target for Dynavax Technologies downward from $22.80 to $21.80. They cite slight adjustments to key financial assumptions, including discount rate, revenue growth, and profit margin forecasts.分析記事 • Nov 08
Dynavax Technologies Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
It's been a good week for Dynavax Technologies Corporation ( NASDAQ:DVAX ) shareholders, because the company has just...Seeking Alpha • Oct 29
Dynavax Technologies Trading At Fair Value
Summary Dynavax's HEPLISAV‑B is its sole revenue generator. HEPLISAV‑B's revenue has grown steadily in a crowded market of hepatitis B vaccines. The market for these vaccines is expected to peak at ~$900 million in 2030 before tailing off afterwards. DVAX expects to grow its percentage share of the hepatitis B market to 60% by 2030. Read the full article on Seeking Alpha分析記事 • May 08
Dynavax Technologies Corporation Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
There's been a notable change in appetite for Dynavax Technologies Corporation ( NASDAQ:DVAX ) shares in the week since...分析記事 • Mar 04
We Think Dynavax Technologies' (NASDAQ:DVAX) Profit Is Only A Baseline For What They Can Achieve
The subdued stock price reaction suggests that Dynavax Technologies Corporation's ( NASDAQ:DVAX ) strong earnings...Seeking Alpha • Mar 03
Dynavax Technologies: A Post-Earnings Assessment With Growing Market Share
Summary Dynavax Technologies posted solid Q4 results and FY 2025 guidance late in February, with Heplisav-B driving revenue growth and profitability. Heplisav-B's market share continues to grow due to its superior efficacy and compliance compared to previous hepatitis B vaccines. Heplisav-B should eventually garner 60% of a market that is predicted to grow to $900 million in the U.S. by 2030. Dynavax Technologies also has large net cash holdings and a promising Shingles vaccine in development. An updated analysis around Dynavax Technologies follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Feb 05
Dynavax Technologies: Time To Refocus On Former Cash Cow CpG1018
Summary HEPLISLAV-B, which is adjuvanted with CpG1018, has key advantages over its principal competition, Engerix-B. The article reviews Dynavax's investment prospects following its Q3 2024 earnings report, preliminary 2024 financial results press release, and latest website presentation. Management's failure to work towards monetizing its CpG1018 adjuvant is unfortunate, in my opinion. Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Read the full article on Seeking Alpha分析記事 • Jan 24
Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Nov 13
Dynavax Technologies: What The Stock Buyback Means, What It Doesn't
Summary Today, we revisit Dynavax Technologies Corporation, whose shares have moved up nicely after the company announced a significant buyback authorization. In addition, DVAX's flagship product, Heplisav-B, continues to increase market share consistently in a growing market. The company has also moved towards profitability, and analyst firms have price targets significantly above the current trading level of the stock, even after its recent rally. An updated analysis around Dynavax Technologies follows in the paragraphs below. Read the full article on Seeking Alpha分析記事 • Nov 12
Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 31% Yet Its Low P/S Is No Reason For Excitement
Dynavax Technologies Corporation ( NASDAQ:DVAX ) shareholders would be excited to see that the share price has had a...分析記事 • Oct 12
Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
新しいナラティブ • Sep 14
HEPLISAV-B And New Vaccine Trials Set To Skyrocket Revenue And Market Share
Strong HEPLISAV-B sales and market optimism indicate potential for revenue growth and market share expansion in the adult hepatitis B vaccine sector.Seeking Alpha • Sep 05
Dynavax Technologies: Slow And Steady Wins The Race
Summary Today, we are revisiting Dynavax Technologies Corporation, one of my favorite “rinse, wash, and repeat” covered call trades recently. Dynavax Technologies' Heplisav-B vaccine continues to gain market share, driving solid revenue growth and profitability despite the loss of COVID-19 adjuvant sales. Despite range bound stock performance, Dynavax's profitability and decent liquidity in the options against the equity, make it an attractive investment, with minimal downside risk and potential for solid upside. An updated analysis following second quarter results in August follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Aug 23
Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
Summary Dynavax has experienced fluctuations in stock performance since the author's initial coverage. HEPLISAV-B is Dynavax's primary revenue source for the foreseeable future, with CpG-1018 currently sidelined. Supported by ample liquidity, Dynavax is evaluating business development on a disciplined basis. Read the full article on Seeking Alpha分析記事 • Aug 14
Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings
Dynavax Technologies Corporation's ( NASDAQ:DVAX ) stock was strong despite it releasing a soft earnings report last...分析記事 • Jul 12
Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...分析記事 • May 22
Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S
With a price-to-sales (or "P/S") ratio of 6.4x Dynavax Technologies Corporation ( NASDAQ:DVAX ) may be sending bullish...Seeking Alpha • May 10
Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain
Summary HEPLISAV-B Q1 revenue was $48 million, showing 10% YoY growth. Dynavax's shingles and Tdap vaccines advanced in clinical stages, with data anticipated in the coming quarters. Dynavax's balance sheet remains robust with a significant cash runway. Dynavax remains a "hold," given the challenging prospects beyond the hepatitis B market. Read the full article on Seeking AlphaSeeking Alpha • Mar 23
Dynavax: Holding Firm Despite Its Missing Cash Cow
Summary Pandemic era CpG 1018 revenues are gone and unlikely to rekindle. HEPLISAV-B revenues create a reliable growing stream of income. Dynavax is fairly valued. Read the full article on Seeking Alpha分析記事 • Mar 06
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Jan 31
Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry
Dynavax Technologies Corporation's ( NASDAQ:DVAX ) price-to-sales (or "P/S") ratio of 4.7x might make it look like a...株主還元
| DVAX | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 0.1% | -3.0% | -0.3% |
| 1Y | 22.0% | 32.9% | 26.7% |
業界別リターン: DVAX過去 1 年間で32.9 % の収益を上げたUS Biotechs業界を下回りました。
リターン対市場: DVAX過去 1 年間で26.7 % の収益を上げたUS市場を上回りました。
価格変動
| DVAX volatility | |
|---|---|
| DVAX Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: DVAXの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: DVAXの weekly volatility ( 11% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1996 | 405 | Ryan Spencer | www.dynavax.com |
ダイナバックス・テクノロジーズ・コーポレーションは、コマーシャルステージのバイオ医薬品企業で、米国および国際的なワクチンの開発・商業化に注力している。同社は、18歳以上の成人におけるB型肝炎ウイルスのすべての既知のサブタイプによる感染を予防するB型肝炎ワクチンHEPLISAV-Bと、HEPLISAV-Bに使用されるアジュバントであるCpG 1018を提供している。また、第2相臨床試験中のペストワクチン候補であるrF1V、50歳以上の成人における帯状疱疹の予防を目的とした第1/2相臨床試験中の治験用ワクチン候補であるZ-1018、および血液透析を受けている成人向けのHEPLISAV-Bも開発している。同社は、卸売業者や専門販売業者を通じて、病院や診療所、総合医療ネットワーク、公衆衛生クリニックや刑務所、国防総省、退役軍人省、小売薬局などに製品を販売している。米国国防総省、Coalition for Epidemic Preparedness Innovations、Zhejiang Clover Biopharmaceuticals, Inc.旧社名はダブルヘリックス・コーポレーションで、1996年9月にダイナバックス・テクノロジーズ・コーポレーションに社名変更。ダイナバックス・テクノロジーズ・コーポレーションは1996年に法人化され、カリフォルニア州エメリービルに本社を置いている。
Dynavax Technologies Corporation 基礎のまとめ
| DVAX 基礎統計学 | |
|---|---|
| 時価総額 | US$1.76b |
| 収益（TTM） | -US$43.40m |
| 売上高(TTM) | US$330.51m |
5.3x
P/Sレシオ-40.6x
PER（株価収益率DVAX は割高か？
公正価値と評価分析を参照収益と収入
| DVAX 損益計算書（TTM） | |
|---|---|
| 収益 | US$330.51m |
| 売上原価 | US$126.91m |
| 売上総利益 | US$203.60m |
| その他の費用 | US$247.00m |
| 収益 | -US$43.40m |
直近の収益報告
Sep 30, 2025
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.38 |
| グロス・マージン | 61.60% |
| 純利益率 | -13.13% |
| 有利子負債／自己資本比率 | 48.9% |
DVAX の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/02/10 09:34 |
| 終値 | 2026/02/09 00:00 |
| 収益 | 2025/09/30 |
| 年間収益 | 2024/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Dynavax Technologies Corporation 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10
| アナリスト | 機関 |
|---|---|
| Elemer Piros | Cantor Fitzgerald & Co. |
| Douglas Buchanan | Citizens JMP Securities, LLC |
| Jason Butler | Citizens JMP Securities, LLC |